WEP-CLINICAL
WEP Clinical Appoints Karl Challender as Chief Operating Officer
WEP Clinical (WEP), a specialist services company that works with sponsors to help patients and physicians gain early access to medicines when no other treatment options are available, has appointed Karl Challender as the company’s Chief Operating Officer. Karl has been brought on to lead the company’s global operations and drive WEP’s growth and development strategy moving forward.
Karl has over 25 years of experience in the pharmaceutical and clinical research industry and brings with him a wealth of functional experience covering areas including Operations, Finance, Logistics, Project Management and Sales. Prior to joining WEP, Karl worked with organisations including Novartis, Alcon, and most recently Worldwide Clinical Trials, where he was instrumental in the successful growth of the organisation.
Jaswinder Khera, Managing Director of WEP, said:
“WEP has grown rapidly over the last few years. We are excited to see this continue and are confident that Karl’s expansive industry experience and expertise will help elevate our position as the global leader in Expanded Access and Named Patient Programs. Karl is an excellent addition to our team and his passion for patient service and delivery excellence is well aligned with our company ethos and goals.”
About WEP
Established in 2008, WEP is a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available. We have offices located in London, United Kingdom; RTP North Carolina, United States; Lisbon, Portugal; and Dublin, Ireland and possess all the necessary licenses allowing us to meet drug access and distribution needs across all regions, worldwide. We are passionate about helping those in need. For more information, please visit www.wepclinical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005667/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MA-TAKEDA/SEAGEN26.5.2022 23:27:07 CEST | Press release
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
IPSEN26.5.2022 23:02:08 CEST | Press release
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
RI-NORDSON-EFD26.5.2022 19:02:12 CEST | Press release
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution
MEDISCA26.5.2022 18:19:08 CEST | Press release
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA
MERCK26.5.2022 18:02:03 CEST | Press release
Merck to Present Latest Research From Oncology Portfolio at ASCO 2022
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom